Who Could Be Blamed in the Case of Discrepant Histology and Serology Results for Helicobacter pylori Detection?
Authors:
- Sabine SkrebinskaSSSabine Skrebinska
- Francis MegraudFMFrancis Megraud
- Ilva DauguleIDIlva Daugule
- Daiga SantareDSDaiga Santare
- Sergejs IsajevsSISergejs Isajevs
- Inta Liepniece-KareleILInta Liepniece-Karele
- Inga BogdanovaIBInga Bogdanova
- Dace RudziteDRDace Rudzite
- Reinis VangravsRVReinis Vangravs
- Ilze KikusteIKIlze Kikuste
- Aigars VanagsAVAigars Vanags
- Ivars TolmanisITIvars Tolmanis
Open Access
- 6 January 2022
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 12 (1) , 133
Abstract
Background. Discrepancies between histology and serology results for Helicobacter pylori detection could be caused by a variety of factors, including a biopsy sampling error, expertise of the pathologist, natural loss of infection due to advanced atrophy, or a false-positive serology in the case of a previous infection, since antibodies may be present in blood following recovery from the infection. Aims. To identify true H. pylori-positive individuals in discrepant cases by serology and histology using real time polymerase chain reaction (RT-PCR) as a gold standard. Methods. Study subjects with discrepant histology and serology results were selected from the GISTAR pilot study data base in Latvia. Subjects having received previous H. pylori eradication therapy or reporting use of proton pump inhibitors, antibacterial medications, or bismuth containing drugs one month prior to upper endoscopy were excluded. We compared the discrepant cases to the corresponding results of RT-PCR performed on gastric biopsies. Results. In total, 97 individuals with discrepant results were identified: 81 subjects were serology-positive/histology-negative, while 16 were serology-negative/histology-positive. Among the serology-positive/histology-negative cases, 64/81 (79.0%) were false-positives by serology and, for the majority, inflammation was absent in all biopsies, while, in the serology-negative/histology-positive group, only 6.2% were proven false-positives by histology. Conclusions. Among this high H. pylori prevalent, middle-aged population, the majority of discrepant cases between serology and histology were due to false positive-serology, rather than false-negative histology. This confirms the available evidence that the choice of treatment should not be based solely on the serological results, but also after excluding previous, self-reported eradication therapy.Keywords
This publication has 24 references indexed in Scilit:
- Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkersScandinavian Journal of Gastroenterology, 2012
- Operative link for gastritis assessment vs operative link on intestinal metaplasia assessmentWorld Journal of Gastroenterology, 2011
- The origin of non-H. pylori-related positive Giemsa staining in human gastric biopsy specimens: A prospective studyDigestive and Liver Disease, 2011
- Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - "ABC method"Proceedings of the Japan Academy, Series B, 2011
- Urease-positive bacteria in the stomach induce a false-positive reaction in a urea breath test for diagnosis of Helicobacter pylori infectionJournal of Medical Microbiology, 2008
- Persisting Chronic Gastritis and Elevated Helicobacter pylori Antibodies after Successful Eradication TherapyHelicobacter, 2007
- Helicobacter pyloriDetection and Antimicrobial Susceptibility TestingClinical Microbiology Reviews, 2007
- Dynamics of Helicobacter pylori -Specific Immunoglobulin G for 2 Years after Successful Eradication of Helicobacter pylori Infection in an American Indian and Alaska Native PopulationClinical and Vaccine Immunology, 2007
- Real-Time PCR Assay for Rapid and Accurate Detection of Point Mutations Conferring Resistance to Clarithromycin in Helicobacter pyloriJournal of Clinical Microbiology, 2003
- Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus ReportAlimentary Pharmacology & Therapeutics, 2002